Lexicon Pharmaceuticals Targets Mid-2026 ZYNQUISTA NDA Resubmission Pending FDA Safety Data Threshold

Lexicon Pharmaceuticals' path to U.S. approval for ZYNQUISTA (sotagliflozin) in type 1 diabetes hinges on a single external variable: whether the STENO1 investigator-initiated study meets the patient exposure and safety data thresholds the FDA identified as prerequisites for NDA resubmission. That dependency places a third-party trial at the centre of Lexicon's regulatory timeline, a structural consideration for affairs leads tracking late-stage cardiometabolic submissions.

Lexicon confirmed the resubmission remains on track for mid-2026, with potential approval before year-end, provided STENO1, conducted by the STENO Diabetes Center in Denmark and funded independently of Lexicon, delivers the required dataset. The NDA, if approved, would position ZYNQUISTA as the first adjunct-to-insulin mechanism for glycemic management in adults with T1D since insulin itself entered clinical use. Sotagliflozin's dual inhibition of SGLT1 and SGLT2 has been evaluated across approximately 20,000 patients in cardiometabolic indications, providing a substantial safety reference base, though the FDA's specific exposure requirements for the T1D indication remain the operative constraint.

On the device and trial operations side, enrollment in SONATA-HCM, a pivotal Phase 3, placebo-controlled study targeting 500 patients with obstructive or nonobstructive hypertrophic cardiomyopathy, is expected to complete mid-2026, with topline data anticipated in the first quarter of 2027. For clinical operations and QA teams supporting the program, that enrollment closure marks the transition to data lock and statistical analysis planning under the registrational protocol.

Lexicon's early-stage pipeline adds a parallel regulatory consideration: in March 2026, licensee Novo Nordisk initiated a Phase 1 single and multiple ascending dose study of LX9851, a first-in-class oral ACSL5 inhibitor targeting obesity and associated metabolic disorders. Phase 1 completion by Novo Nordisk is anticipated within the next 12 months, at which point development milestone obligations under the license agreement become relevant to Lexicon's financial planning.

The company's financial position has been reinforced by a recent capital raise, two development milestone payments from Novo Nordisk received earlier in 2026, and a $100 million loan facility. Outside the U.S. and Europe, licensee Viatris has secured regulatory approval in the United Arab Emirates and submitted applications in Canada, Australia, and New Zealand, with additional market filings planned through 2026, a supply-chain and CMC coordination point for teams supporting ex-U.S. commercial readiness.

The measurable checkpoint for regulatory and QA leads is the STENO1 data package: its adequacy against the FDA's stated patient exposure and safety criteria will determine whether Lexicon's mid-2026 resubmission timeline holds.

Source: Lexicon Pharmaceuticals via GlobeNewswire, 7 May 2026.